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chronic viral hepatitis C (HCV).
Methods: Cytogenetic examination was performed in three patients
groups: 23 patients with ESRF on HD; 21 patient having HCV with
ESRF on HD; 29 patients with HCV without renal function disorder.
Lymphocytes were cultivated according to the conventional Hun-
gerford method for 52 hours with modiﬁcations. Selection of met-
aphasal plates for cytogenetic analysis, classiﬁcation and method for
calculation of chromosome aberrations were conventional. Multi-
aberrant cells were considered those having 3 aberrations and more.
Aneuploid cells were divided into hypoploid (under 42) and hy-
perploid ones (over 49).
Results: The frequency of chromosome aberrations was conﬁdently
different in all the three groups of patients examined and exceeded
the norm (by 3%). The highest indexes were in patients with HCV
(17,78  0,55%, P < 0,05) which was the cosequence of virus-
induced mutagenesis and were conﬁrmed by the data of other
authors. An intermidiate result (10,60  1,49%, P < 0,05) of chro-
mosome aberrations frequency in patients having HCV with ESRF
might suggest the impact of HD procedure on the chronic hepatitis
ﬂow in this patients’ category. In patients with ESRF this index was
conﬁdently lower than in other patients groups (4,69  0,51%).
In patients with ESRF on HD a number of aneuploid cells was
conﬁdently higher (20,0  0,97%, P < 0,05) and hence one may
suppose the presence of oncogenic component. In patients group with
HCV on HD and those without renal function disorder this index was
lower and made 14,12  1,69% and 16,32  0,53% accordingly. The
virus in case of a durable replicative phase is an inductor of a chain of
events leading to severe and mass demages of chromosome material.
This is conﬁrmed by the highest level of multiaberrant cells 7,71 
0,38% in patients with HCV. In patients with HCV on HD a number
of multiaberrant cells was conﬁdently lower and made 2,35  0,74%,
which didn’t differ from the indexes of patients with ESRF on HD
without hepatitis. In patients with HCV the largest chromosome
aberration spectrum was ﬁxed, that included acentric rings and
translocations, indicating its virus-induced damages.
A single hemodialysis procedure had no impact on the chro-
mosome aberrations level: the frequency of metaphases with aber-
rations remained on pre-dialysis level.
Conclusions:Hemodialysis procedure has an effect on the HCV ﬂow
and neutralizes the virus impact on genetic apparatus in case of
those pathologies combined. Our data allow one to explain and
conﬁrm the results of other researchers stating that the HCV ﬂow in
patients on program hemodialysis is less aggressive.
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Introduction: Chronic kidney disease (CKD) affects 8-16% people
worldwide, with an increasing incidence and prevalence of end-
stage kidney disease (ESKD). The effective management of CKD is
currently confounded by the inability to identify patients at high
risk of progression while still in early stages of CKD. Identifying the
mechanism responsible for progression of CKD is a critical step to
contain the worldwide CKD epidemic. A molecular disease deﬁni-
tion of CKD will allow us to develop strategies for patient risk
stratiﬁcation to prioritize limited health care resources, to identify
targeted molecular therapies for patients at high risk and to develop
biomarkers to deﬁne such patients for clinical trials. Our hypothesis
is that both clinical phenotypes (e.g. GFR, proteinuria) and renal
tissue alterations seen in CKD are associated with, and a conse-
quence of, the dynamic molecular mechanism reﬂected in the
transcriptional programs of the diseased renal tissue.
Methods: Our work started from the identiﬁcation and cross-vali-
dation of pathways and candidate intrarenal biomarkers for CKD
progression in 261 kidney biopsies. We then used a sequential
prioritization strategy to prioritize candidates for non- invasive
biomarkers to allow broad clinical applicability. Next, intra-renal
transcript levels of the top candidate biomarker were correlated
with the urinary levels of the encoded proteins. Urinary protein
levels were assessed for their correlation with CKD progression.
Finally, the biomarker was tested for its ability to increase pre-
dictive power of established clinical marker panels for CKD pro-
gression prediction in three cohorts. We used Cox proportional
hazards models to evaluate the predictive value of marker on CKD
outcome, and used likelihood ratio tests, C-statistics, and Akaike
information criterion (AIC) to assess the goodness of ﬁt and
improved prediction ability. Finally, we present our effort in
identiﬁcation the molecular disease mechanism, serving as targets,
to develop novel therapies to prevent CKD progression.
Results: Using Epidermal Growth Factor (EGF) as a proof of prin-
ciple, we could demonstrate that prediction of renal survival by
eGFR and albuminuria was signiﬁcantly improved by addition of
uEGF to the model in diverse CKD populations with a wide spec-
trum of causes and stages. uEGF may contribute to the improved
risk prediction as it can capture the degree of tubular differentia-
tion and regeneration potential, mechanisms essential to retain renal
function with the acute and chronic insults seen in CKD, but not be
well reﬂected by the conventional predictors (proteinuria or base-
line GFR).
Conclusions: uEGF shows promise as an independent risk predictor
of CKD progression. Inclusion of uEGF signiﬁcantly improved
prediction of composite end points by eGFR and proteinuria in
diverse populations worldwide with a wide range of CKD. An
immediate beneﬁt of our work can be an improved stratiﬁcation of
CKD patients for the selections of high-risk patients into clinical
trials, addressing a critical hurdle for novel molecular target vali-
dation in CKD.
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Introduction: The molecular events occurring within the human
kidney during treatment of lupus nephritis (LN) are unknown. We
previously reported that the immune proﬁle of LN biopsies at ﬂare
is different between complete responders (CR) from non- re-
sponders (NR). Here, we evaluate whether the differences in renal
transcript expression after induction therapy can distinguish bi-
opsies that end in CR and NR and identify a set of markers asso-
ciated with treatment response and non-response.
Methods: The expression of 511 immune-response genes was
determined in kidney biopsies from 19 patients with proliferative
LN and 4 normal controls using Nanostring technology. Biopsies
were done at ﬂare (Bx1) and after induction therapy (Bx2). After
induction, 5 patients achieved CR, 4 patients had an NR and 10
patients achieved a PR by clinical metrics (24 hour urine protein-
uria and serum creatinine).
Results: Transcript expression was measured at Bx1 and Bx2 in all
patients and compared to normal controls. Additionally, the change
in expression from Bx1 and Bx2 was compared within each group
and between groups. Transcripts were considered differentially
expressed if they achieved both a p-value of <0.05 and at least a 1.5
fold change. From Bx1 to Bx2, transcripts that signiﬁcantly
changed in ﬂares that ended in CR included increased expression of
NCAM1 (FC-2.24, P¼0.004), and decreased expression of IL1RL1
(FC: -3.13, P¼0.001), FKBP5 (FC: -4.76, P¼0.009), FCAR (FC: -2.04,
P¼0.011), and IL17 (FC: -1.7, P¼0.018).
Transcript expression analysis in ﬂares that ended in NR iden-
tiﬁed an 11-gene signature including increased expression of IL17
(FC: 1.66, P¼0.044), IL1RAP (FC: 2.19, P¼0.001), CD5 (FC: 2.38,
P¼0.009), and decreased expression of C7 (FC:-3.45, P¼0.001),
IL28B (FC:2.77, P¼0.003), and IL12RB1 (FC: -2.38, P¼0.004).
Between ﬂare and repeat biopsy, a 10-gene signature differentiated
ﬂares that ended in NR compared to CR and included increased
expression of IL17, IL1RAP, and iNOS and decreased expression of
NCAM1, and IL28B. Furthermore, neutrophil associated transcripts
(NCF4, LTF, CSF2RB, and CSF3R) and alternative complement
pathway component transcripts (increased C3, CFB, CFD and
decreased CFI, CD55, CD59) were more abundantly expressed in NR
biopsies compared to normal and CR biopsies with increasing
expression from Bx1 to Bx2 in the NR group.
Conclusions: These data suggest that the immunologic changes that
occur in a kidney biopsy after treatment of LN are different in ﬂares
that end in CR compared to NR. Increases in NCAM1 and IL28 may
predict response to treatment while increases in IL17 may reﬂect
non-response. Additionally, persistent neutrophil inﬁltration and
alternative pathway activation may play a role in preventing
response to standard therapy. Comparing the immunologic changes
within the kidney during successful and unsuccessful treatment
may identify novel therapeutic targets for LN and biomarkers of
response and non-response.
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Introduction: Injury in glomerulonephritis may be associated with
“proteotoxicity” due to protein misfolding, and induction of
endoplasmic reticulum (ER) stress and polyubiquitination. Exam-
ples include complement-induced glomerular epithelial cell (GEC)/
podocyte injury in membranous nephropathy, and focal segmental
glomerulosclerosis (FSGS). Podocyte injury due to proteotoxicity
can also result from mutations in integral proteins, which lead to
their misfolding and accumulation. We assessed if small molecule
modulators of proteostasis or accelerated removal of misfolded
proteins by the ubiquitin-proteasome system (UPS) can ameliorate
the proteotoxicity of misfolded proteins, using GEC culture and in
vivo models of glomerular injury.
Methods:We employed 4-phenylbutyric acid (4-PBA), a compound
that can improve protein folding by increasing the strength of
intramolecular hydrophobic bonds, or lowering a protein’s free
energy state, as well as celastrol, a drug that improves folding via
increasing expression of ER and cytosolic chaperones. Moreover, to
accelerate removal of misfolded proteins by the UPS, we employed
IU1, a compound that inhibits ubiquitin-speciﬁc protease 14
(Usp14), a deubiquitinating enzyme that retards proteasomal pro-
tein degradation.
Results: In cultured GECs stimulated with tunicamycin, 4-PBA
markedly reduced ER stress, as monitored by a reduction of stim-
ulated transcriptional activity of activating transcription factor-6
and reduction of stimulated expression of the ER chaperone, BiP.
Incubation of GECs with celastrol enhanced expression of BiP, heat-
shock protein (Hsp)-70, and transcriptional activity of heat shock
factor-1, which induces cytosolic chaperones, such as Hsp70. To
address complement cytotoxicity, GECs were incubated with anti-
body and serially-increasing doses of complement. This protocol
allows for complement to induce ER stress, but with increasing
incubation time and complement dose, a portion of the cells un-
dergoes lysis. Complement-mediated lysis in GECs was attenuated
signiﬁcantly by 4-PBA and celastrol. The UPS reporter proteins,
GFPu (a cytosolic “misfolded” protein) and CD3 (an ER-associated
degradation substrate) undergo time-dependent proteasomal
degradation in GECs. The Usp14 inhibitor, IU1, accelerated
the degradation of both misfolded reporter proteins by the pro-
teasome. IU1 did not, however, affect complement-induced GEC
cytotoxicity. The -actinin-4 K256E mutant, which induces FSGS in
humans, showed enhanced ubiquitination, formed aggregates, and
disrupted ER function in cultured GECs. 4-PBA and celastrol both
reduced -actinin-4 K256E aggregation. -actinin-4 K256E transgenic
mice develop podocyte injury, proteinuria and FSGS, in association
with glomerular ER stress. Treatment of these mice with 4-PBA in
the drinking water over a 10 week period signiﬁcantly reduced
albuminuria, and glomerular expression of the proapoptotic ER
stress protein, CHOP.
Conclusions: Podocyte injury associated with protein misfolding
was reduced by compounds that can improve protein folding either
directly or via enhanced expression of chaperones. Small molecule
proteostasis regulators may represent a novel therapeutic approach
to glomerulonephritis.
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